FDA Warning Letter to R3 Medical Companies (August 2026): Stem Cell and Exosome Enforcement, CGMP Charges, and Criminal Exposure
FDA's newest stem cell warning letter reaches an entire enterprise. On August 25, 2026, FDA posted a warning letter to R3 Medical Companies of Scottsdale, Arizona, covering four umbilical cord, Wharton’s Jelly, and exosome products in the ReBella line. The letter is different from the website-review letters that preceded it. It rests on facility inspections and dual Form 483s, adds manufacturing-quality adulteration charges, quotes the company’s TikTok and YouTube content as evidence, and reminds the CEO that FDA first warned him in 2019. It also states that the exosome products may not contain exosomes at all.
Overview: Why This Letter Is Different
On August 25, 2026, FDA posted a warning letter to R3 Medical Companies, issued August 14, following inspections of two co-located Scottsdale facilities: Bello Bio, the contract manufacturer, and Regen Suppliers, the private-label distributor. The letter covers ReBellaWJ, ReBellaXO, ReBellaXOL, and ReBellaCB, and finds them unapproved new drugs, unlicensed biologics, and adulterated drugs manufactured in violation of CGMP.
The evidentiary record is the company’s own media: YouTube, TikTok, Instagram, Facebook, and three websites, quoted at length in the letter. FDA also states that the products marketed as exosomes are made by a process that does not appear to isolate exosomes, and that it notified the same CEO of the same legal problem in a letter dated May 28, 2019.
The response clock is 15 working days. The stakes are higher than in a website-review letter: adulteration charges, product in the field manufactured under unvalidated sterile processes, an inadequate Form 483 response already on the record, and seven years of documented notice, which is the evidence prosecutors use to convert FDCA misdemeanors into felonies under 21 U.S.C. § 333(a)(2).
FDA’s campaign against unapproved stem cell and exosome products has run for two years on a website-review model: the agency reads a clinic’s treatment claims, matches them against the product’s regulatory status, and mails the letter. We analyzed that model, and the letters it produced through early 2026, in our review of FDA warning letters on exosome products.
The August letter is a different instrument. FDA investigators spent a month inside the facilities, from November 17 to December 16, 2025. They issued a Form 483 to the manufacturer and a separate Form 483 to the distributor. The agency then reviewed the company’s written responses, found them inadequate, and said so in the letter. What emerged is the most complete enforcement document CBER has produced in this space this year: product claims, manufacturing failures, corporate structure, and prior notice, assembled in one place. Anyone operating in regenerative medicine should read it as a template, because the next letter will follow it.
The August 14 Letter: One Enterprise, Four Products
The warning letter is addressed to the chief executive officer of R3 Medical Companies, a physician. FDA’s footnotes map the structure he sits atop: Bello Bio, LLC contract manufactures and labels the umbilical cord derived products; Regen Suppliers, LLC approves, labels, stores, and distributes them under private label; R3 Stem Cell, LLC markets them; and R3 Anti-Aging clinics in Scottsdale, Nashville, and Beverly Hills administer them, with additional reach through a partnership program for outside providers. The letter states that the CEO bears primary responsibility for the business operations of each entity. The corporate layering earned no separation. It earned a footnote.
Four products carry the charges. ReBellaWJ is derived from Wharton’s Jelly. ReBellaXO and ReBellaXOL are marketed as exosome products, the latter lyophilized. ReBellaCB is derived from umbilical cord blood. FDA also flagged a parallel Bello-branded line in its additional-concerns section. None of the products is covered by a biologics license application or an investigational new drug application.
The Claims: Quoted From the Company’s Own Feeds
The intended-use evidence spans every channel the company operated. FDA cited the R3 Stem Cell YouTube channel, its TikTok and Instagram accounts, its Facebook page, and three websites, all last visited August 2026. The quoted claims include a blog post stating that the cells “systemically reduce” the chronic inflammation behind organ failure, arthritis, and several types of cancer; a conditions list naming autism, cerebral palsy, diabetes, Lyme disease, COPD, cardiomyopathy, and erectile dysfunction; and exosome pages claiming the particles penetrate the blood-brain barrier with possible future benefit for Alzheimer’s, Parkinson’s, and stroke recovery.
One piece of evidence stands apart. FDA quoted a video posted March 5, 2026, titled “Elite Football Player Talks to His Stem Cells,” in which an employee shows vials of ReBellaCB and ReBellaXO to a patient and says, “These are your stem cells. There’s 30 million in each vial.” A marketing video became a regulatory admission with a timestamp. The letter also footnotes that one company website returned a “404, Not Found” message by the letter’s issue date. Taking a site down after an inspection removes nothing. FDA had already captured it.
The legal consequence of the claims is fixed. Products promoted to treat disease are drugs under 21 U.S.C. § 321(g)(1) and biological products under 42 U.S.C. § 262(i). The letter walks the familiar path under 21 CFR 1271.10(a): the products fail the homologous use criterion because treating arthritis and inflammation is not the basic donor function of umbilical cord or cord blood, and the cord blood product independently fails the criterion governing products that depend on the metabolic activity of living cells. Without a license under § 262(a)(1) or an IND, distribution in interstate commerce is prohibited under 21 U.S.C. § 331(d) and § 355(a).
The CGMP Charges: What the Inspections Added
Website-review letters end with the licensing analysis. This one keeps going. Because the products are drugs, their manufacture must conform to current good manufacturing practice, and FDA charged that it did not, rendering the products adulterated under 21 U.S.C. § 351(a)(2)(B). Six violations are charged under 21 CFR Part 211.
The findings go to sterility and shelf life, the two properties an injectable product cannot fake. The firm never validated the aseptic processes used to make products that purport to be sterile, as 21 CFR 211.113(b) requires. It never validated the manufacturing process for identity, strength, quality, and purity under § 211.100(a). Its sterility testing had a built-in blind spot: samples were frozen and thawed before testing, which can destroy microbial content and mask contamination, defeating the laboratory-control requirement of § 211.160(b). Cleaning of the biological safety cabinet where product sits exposed was never validated. The products carry a 24-month expiration date supported by no stability data, contrary to § 211.166(a). And the quality unit had no written procedures at all, including none for approving or rejecting product or handling complaints.
FDA applied the CGMP charges to the distributor as well as the manufacturer. A footnote explains why: Regen’s approving, labeling, storing, and distributing activities constitute manufacturing under 21 CFR 210.3(b)(12). Private-label distribution is not a liability shield. It is a second regulated manufacturing operation with its own Form 483.
The Exosome Finding: Products That May Not Be What the Label Says
Two footnotes carry the letter’s most consequential finding. FDA states that the products marketed as exosomes are made by a manufacturing process that “does not appear would isolate exosomes.” The regulatory violation does not depend on that fact; a product sold to treat disease is an unapproved drug whatever the vial holds, and FDA’s Public Safety Notification on Exosome Products confirms no exosome product is approved for any use. The fraud exposure does depend on it. A company charging clinics and patients for exosome therapy, from a process that cannot isolate exosomes, has a product-content problem that sounds in wire fraud under 18 U.S.C. § 1343, supplies the intent-to-defraud element of the FDCA felony, and invites FTC action and purchaser suits. When the government can prove the product is not what the label says, the case stops being about licensing.
Seven Years of Notice
The letter’s quietest paragraph is its most dangerous. FDA recites that it sent the same CEO a letter dated May 28, 2019, stating that the stem cell therapies promoted on the company’s website for ALS, diabetes, kidney failure, Lyme disease, Parkinson’s disease, and stroke were nonhomologous uses regulated as drugs and biologics. The agency then observes that its current review of the websites and social media accounts shows the same offerings continue.
“However, our review of your current websites and various social media accounts… indicates umbilical stem cell therapy and exosome therapy continue to be offered… for treatment of various diseases and conditions.”
— FDA Warning Letter to R3 Medical Companies, CBER 26-726330 (Aug. 14, 2026)That paragraph is a criminal exhibit in draft. Any violation of the prohibited acts in 21 U.S.C. § 331 is a strict-liability misdemeanor under § 333(a)(1), and under United States v. Park, 421 U.S. 658 (1975), an executive with authority over the violation needs no personal knowledge to be convicted of it. The felony provision, § 333(a)(2), requires intent to defraud or mislead and carries three years per count. Intent is proven with notice plus continuation. Here the notice is a 2019 letter addressed to the executive by name, and the continuation is documented through August 2026 in the company’s own posts. Seven years is not a compliance gap. To a prosecutor, it is the timeline slide.
The Inadequate 483 Response
Both facilities responded to their Form 483s in January 2026 and committed to temporarily suspend manufacturing. FDA reviewed the responses and rejected them, with reasons stated: no plan addressing continued distribution, no disposition plan for inventory manufactured under the violative conditions, nothing addressing distributed product still within its 24-month expiration date, corrections asserted without supporting documentation, and no answer to the core defect, the absence of any IND or BLA.
Each gap has a next act. Unexpired product in the field, made under unvalidated sterile processes, is the public-health showing FDA uses for seizure under 21 U.S.C. § 334 and injunction under § 332, remedies the letter expressly reserves. Distribution that continued after the inspection is conduct after notice. And the responses themselves are written statements to a federal agency: discoverable, quotable, and subject to 18 U.S.C. § 1001 if any representation in them proves false. A suspension of manufacturing announced in a 483 response resolves nothing if the licensing violation and the field inventory remain. FDA said exactly that.
Who Should Read This Letter Closely
The letter’s structure tells the market who is next. Contract manufacturers making cord, amniotic, or exosome products for other people’s labels now know the 361-tissue defense will be tested against 1271.10(a) product by product, and that CGMP charges follow when it fails. Private-label distributors now know their labeling and holding activities make them manufacturers under 210.3(b)(12). Clinic chains and their alliance or affiliate networks now know FDA will name the parent, the clinics, and the investment vehicle in the footnotes and assign responsibility to the executive at the top. Physicians fronting these operations should note that the addressee here, like the addressees of the earlier clinic letters, is a licensed doctor whose board reads public FDA findings. And any company that received an untitled letter or notice years ago and kept selling should understand what that history now does to the intent element. The marketing lives forever in FDA’s capture files. The 404 page proves it.
Armstrong & Bradylyons PLLC: Stem Cell and Regenerative Medicine Defense
Armstrong & Bradylyons PLLC defends manufacturers, distributors, clinics, executives, and physicians in FDA enforcement matters and the criminal and civil investigations that grow out of them, through its stem cell and regenerative medicine fraud defense practice. The work includes warning letter and Form 483 responses, seizure and injunction defense, grand jury representation, and trial.
Scott Armstrong served as Director of DOJ’s Appalachian Regional Prescription Opioid Strike Force, as an Assistant Chief in the Fraud Section’s Market Integrity and Major Frauds Unit, and as a leading trial attorney in its Healthcare Fraud Unit. He tried sixteen federal jury trials, including nine healthcare fraud trials, and served as lead counsel in cases totaling over $600 million in false claims to federal programs. He built prosecutions from precisely the materials this letter assembles: marketing claims, inspection findings, corporate structures, and the gap between what a company sold and what the law allowed.
Drew Bradylyons served as an Assistant Chief in DOJ’s Health Care Fraud Unit, where he supervised the Miami Strike Force, and as Chief of the Financial Crimes and Public Corruption Unit at the U.S. Attorney’s Office for the Eastern District of Virginia, where he supervised parallel civil, criminal, and administrative proceedings involving more than $1 billion in claims to Medicare, Medicaid, and TRICARE. He knows how a 483 response becomes a grand jury exhibit, because he supervised cases built that way.
The firm’s attorneys have over 25 years of combined DOJ experience and 25 federal jury trials, including 17 in healthcare fraud cases involving over $2.8 billion in alleged false claims. The firm is based in Washington, D.C. and handles matters in every federal district.
Frequently Asked Questions
What did FDA’s August 2026 warning letter to R3 Medical Companies find?
The letter, issued August 14, 2026 and posted August 25, followed inspections of two co-located Scottsdale facilities: Bello Bio, which contract manufactures umbilical cord derived products, and Regen Suppliers, which labels and distributes them under private label. The cited products are ReBellaWJ, a Wharton’s Jelly product, ReBellaXO and ReBellaXOL, marketed as exosomes, and ReBellaCB, a cord blood product. FDA found them unapproved new drugs under 21 U.S.C. § 355(a) and unlicensed biologics under 42 U.S.C. § 262(a)(1), with no BLA or IND in effect.
The letter also charges adulteration under 21 U.S.C. § 351(a)(2)(B) based on six CGMP violations, including unvalidated aseptic processing for purportedly sterile products, sterility samples frozen before testing, a 24-month expiration date with no stability data, and a quality unit with no written procedures. The response deadline is 15 working days, with seizure and injunction reserved.
Can FDA use social media posts and YouTube videos as evidence of illegal drug claims?
Yes. A product’s regulatory status turns on intended use, and intended use is shown by labeling, advertising, and other indications of the manufacturer’s objective intent under 21 CFR 1271.3(c). The August letter cites the company’s YouTube channel, TikTok, Instagram, Facebook page, and three websites, and quotes them: claims that the cells systemically reduce inflammation tied to organ failure and cancer, condition lists naming autism, diabetes, Lyme disease, and COPD, and exosome claims about crossing the blood-brain barrier for Alzheimer’s and Parkinson’s.
FDA even quoted a March 2026 video in which an employee shows vials to a patient and says there are 30 million stem cells in each one. Every post is an admission with a date. Deleting content does not help; the letter footnotes that one company website returned a 404 error by the issue date, after FDA had captured it.
What does it mean that FDA said the exosome products may not actually contain exosomes?
Two footnotes state that the products marketed as exosomes come from a manufacturing process that does not appear to isolate exosomes. The regulatory violation stands either way: a product sold to treat disease is an unapproved drug regardless of contents, and FDA’s exosome safety notification confirms no exosome product is approved for any use.
The fraud exposure is what changes. Charging clinics and patients for exosome therapy from a process that cannot isolate exosomes is a misrepresentation about the product itself, made across state lines for money. That is the factual core of wire fraud under 18 U.S.C. § 1343, the intent-to-defraud element of the FDCA felony under 21 U.S.C. § 333(a)(2), and the basis for FTC actions and purchaser suits. Product-content findings move a case from the regulatory lane to the fraud lane.
How does a prior FDA notice letter increase criminal exposure?
Notice is the raw material of felony intent. Any violation of the prohibited acts in 21 U.S.C. § 331 is a misdemeanor under § 333(a)(1) with no intent requirement, and under United States v. Park, 421 U.S. 658 (1975), an executive with authority over the violation can be convicted without personal knowledge. A violation committed with intent to defraud or mislead is a felony under § 333(a)(2), three years per count.
The August letter builds the intent record itself: FDA notified the same CEO by letter dated May 28, 2019 that the therapies promoted for ALS, diabetes, Parkinson’s disease, and stroke were regulated as drugs and biologics, and its 2026 review found the same offerings still up. Seven years of continuation after personal, written notice is exactly the evidence prosecutors use to charge the felony rather than the misdemeanor.
Are contract manufacturers and private-label distributors both liable for CGMP violations?
Yes, and this letter charges both. FDA issued separate Form 483s to the manufacturer and the distributor and applied CGMP charges to each, explaining in a footnote that the distributor’s approving, labeling, storing, and distributing activities constitute manufacturing under 21 CFR 210.3(b)(12). A firm that never touches a bioreactor still carries manufacturer obligations if it labels or holds the product.
The letter also rejected the manufacturer’s position that it was a section 361 tissue establishment subject only to good tissue practice rules, because the products fail the criteria in 21 CFR 1271.10(a). And the corporate layering, a parent company, a manufacturer, a distributor, a marketing entity, and affiliated clinics, produced no separation: FDA named each entity and stated that the chief executive bears primary responsibility for the operations of all of them.
What happens when FDA finds a Form 483 response inadequate?
The warning letter says so publicly, and the stated gaps become the roadmap. Here FDA rejected the January 2026 responses on specific grounds: no plan for continued distribution, no disposition plan for inventory made under violative conditions, nothing addressing distributed product still within its expiration date, corrections lacking documentation, and no answer to the absence of an IND or BLA. A committed temporary manufacturing suspension did not cure any of it.
Each gap has consequences. Unexpired product in the field made under unvalidated sterile processes supports seizure under 21 U.S.C. § 334 and injunction under § 332. Distribution after inspection findings is conduct after notice. And a 483 response is a written statement to a federal agency, discoverable in later proceedings and subject to 18 U.S.C. § 1001 if false. It is the first exhibit, drafted by the company itself.
Where does Armstrong & Bradylyons PLLC defend stem cell and regenerative medicine investigations?
Armstrong & Bradylyons PLLC defends manufacturers, private-label distributors, clinics, executives, and physicians in FDA warning letter and Form 483 responses, seizure and injunction actions, grand jury investigations, and trial, through its stem cell and regenerative medicine fraud defense practice.
Scott Armstrong served as Director of DOJ’s Appalachian Regional Prescription Opioid Strike Force, as an Assistant Chief in the Fraud Section’s Market Integrity and Major Frauds Unit, and as a leading trial attorney in its Healthcare Fraud Unit, trying sixteen federal jury trials with lead-counsel responsibility for cases totaling over $600 million in false claims. Drew Bradylyons served as an Assistant Chief in the Health Care Fraud Unit, where he supervised the Miami Strike Force, and as Chief of the Financial Crimes and Public Corruption Unit at the U.S. Attorney’s Office for the Eastern District of Virginia, supervising parallel civil, criminal, and administrative proceedings involving more than $1 billion in claims.
The firm’s attorneys have over 25 years of combined DOJ experience and 25 federal jury trials, including 17 in healthcare fraud cases involving over $2.8 billion in alleged false claims. The firm is based in Washington, D.C. and handles matters in every federal district.
